BHRT Research Timeline

Significance

Triggered an immediate 68% decline in HRT prescriptions globally. Later analyses revealed the findings were specific to older postmenopausal women given synthetic progestin — not applicable to younger women beginning therapy at menopause onset or to bioidentical formulations.

Significance

Began to separate the risks of synthetic progestins from estrogen itself, and suggested that cardiovascular risk depended heavily on when therapy was initiated relative to menopause.

Significance

Established the mainstream medical position on BHRT. Widely cited by those skeptical of compounded preparations, though it has been criticized for conflating compounded BHRT with FDA-approved bioidentical formulations like estradiol patches and micronized progesterone.

Significance

The most compelling evidence for the 'timing hypothesis' — that hormone therapy begun in early menopause (rather than years later) has cardiovascular protective rather than harmful effects. Often cited as the European counterpart to the WHI.

Significance

Provided direct evidence supporting early intervention and the safety advantage of transdermal over oral estrogen routes. Supported the distinction between FDA-approved bioidentical transdermal estradiol and older oral synthetic formulations.

Significance

One of the largest longitudinal studies of pellet therapy specifically. Frequently cited by practitioners to support the safety and efficacy of subcutaneous testosterone pellets in women, a use that remains off-label and largely absent from mainstream guidelines.

Significance

Reversed the post-WHI guidance that limited HRT to minimum dose and shortest duration. Signaled a major shift in mainstream medical opinion and supported longer-term therapy for appropriate candidates. Updated and reinforced in subsequent annual position statements.

Significance

The first major society guideline to formally acknowledge testosterone therapy for women, though it stopped short of recommending it for non-sexual indications. Highlighted the critical gap: no FDA-approved testosterone product exists for women despite evidence of benefit.

Significance

The first randomized controlled trial to directly test the timing hypothesis for cardiovascular protection. Provided the strongest controlled evidence that early initiation of estradiol — but not late initiation — confers cardiovascular benefit.

Significance

Provided some of the longest follow-up data supporting hormone therapy's durable cardiovascular benefits when initiated at menopause onset. The legacy effect — sustained benefit even after stopping — is clinically significant for counseling patients.

Significance

One of the most comprehensive analyses of HRT and breast cancer to date. The findings apply primarily to synthetic progestins (not bioidentical progesterone) and became a reference for ongoing risk-benefit discussions. Bioidentical progesterone was associated with a significantly lower breast cancer signal than synthetic progestins in observational data.

Significance

A formal scientific reconsideration of the study that most shaped (and arguably distorted) HRT practice for two decades. Helped rehabilitate hormone therapy's evidence base and supported the case for early, bioidentical-forward treatment approaches.

Significance

The most recent authoritative guidance on hormone therapy from North America's leading menopause organization. The endorsement of individualized long-term therapy for appropriate candidates represents the current clinical standard of care for patient counseling.

Significance

Established the first global consensus on women's testosterone therapy and reinforced the call for a regulatory pathway for a licensed testosterone product for women — addressing a long-standing clinical and regulatory gap.